Avicanna develops potential cannabinoid-based treatment for COVID-19
June 23, 2020 By Grow Opportunity staff
Toronto-based biopharmaceutical company, Avicanna Inc., announced that it is collaborating on a cannabinoid-based treatment for lung inflammation associated with COVID-19.
The company is working with Dr. Christine Allen’s Research Group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Dr. Allen is a global leader is research and development of pharmaceutical formulations and has a long-standing working relationship with Avicanna for developing cannabinoid-based products.
Avicanna and CARG are hoping to fast-track the development of its pharmaceutical formulation of cannabinoids that aid in the treatment of lung inflammation in patients suffering severe symptoms of COVID-19.
“We are excited to expand our research collaboration with Dr. Allen’s group at the University of Toronto with support from the Mitacs research internship program,” said Dr. Justin Grant, executive vice-president of scientific affairs at Avicanna.
“This funding will allow us the necessary resources to complete pre-clinical studies of our most promising cannabinoid formulations. We feel this is a project that may provide a significant impact.”
Mitacs is a not-for-profit organization funded by the Government of Canada to support growth an innovation in Canada that solves business challenges through research from academic institutions.
Print this page